Page last updated: 2024-10-15
albuvirtide
Description
albuvirtide: an HIV fusion inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 134694278 |
| CHEMBL ID | 4297257 |
| MeSH ID | M0575097 |
Synonyms (11)
| Synonym |
|---|
| albuvirtide |
| DB15166 |
| labuvirtide |
| MG9PC54E43 , |
| labuvirtide [inn] |
| fb-006m |
| albuvirtide [who-dd] |
| 1417179-66-8 |
| CHEMBL4297257 |
| unii-mg9pc54e43 |
| 2395796-76-4 |
Research Excerpts
Overview
Albuvirtide (ABT) is a 3-maleimimidopropionic acid (MPA)-modified peptide HIV fusion inhibitor. It can irreversibly conjugate to serum albumin.
| Excerpt | Reference |
|---|---|
| "Albuvirtide is a once-weekly injectable human immunodeficiency virus (HIV)-1 fusion inhibitor. " | ( Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. Cai, WP; Chen, JF; Chen, YY; Dai, LL; He, Y; Hu, JH; Jiang, TY; Li, LH; Liu, L; Lu, HZ; Lu, RJ; Lun, WH; Peng, HY; Shao, YM; Su, B; Sun, LJ; Sun, YT; Wang, H; Wang, M; Wang, MX; Wang, Y; Wu, H; Xia, W; Xie, D; Xing, H; Yao, C; Yu, JH; Zhang, FJ; Zhang, T; Zhao, M; Zhao, QX; Zheng, QS; Zheng, YH; Zhu, B, 2020) |
| "Albuvirtide (ABT) is a 3-maleimimidopropionic acid (MPA)-modified peptide HIV fusion inhibitor that can irreversibly conjugate to serum albumin. " | ( Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. Cai, L; Chong, H; Cui, S; He, Y; Wang, Y; Yao, X; Zhang, C, 2012) |
Toxicity
| Excerpt | Reference |
|---|---|
| " The frequency of grade 3 to 4 adverse events was similar in the two groups; the most common adverse events were diarrhea, upper respiratory tract infections, and grade 3 to 4 increases in triglyceride concentration." | ( Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. Cai, WP; Chen, JF; Chen, YY; Dai, LL; He, Y; Hu, JH; Jiang, TY; Li, LH; Liu, L; Lu, HZ; Lu, RJ; Lun, WH; Peng, HY; Shao, YM; Su, B; Sun, LJ; Sun, YT; Wang, H; Wang, M; Wang, MX; Wang, Y; Wu, H; Xia, W; Xie, D; Xing, H; Yao, C; Yu, JH; Zhang, FJ; Zhang, T; Zhao, M; Zhao, QX; Zheng, QS; Zheng, YH; Zhu, B, 2020) |
Compound-Compound Interactions
| Excerpt | Reference |
|---|---|
| " Albuvirtide (ABT), a new peptide drug, is a long-acting HIV fusion inhibitor with limited drug-drug interactions and fast onset time." | ( Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS. Cheng, J; He, S; He, Y; Liu, H; Lu, C; Yang, T; Yao, Y; Yin, K; Zhou, R, 2023) |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (28.57%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (14.29%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (57.14%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||